3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Interventions
Cyclophosphamide
2
pembrolizumab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
CLR1404
1
CA-4948
1
Busulfan
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
CLR1404
×
90 days
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled